title: Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
authors.affiliation: Cardiovascular Division of the Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Gibson
authors.forename: J L
authors.initials: JL
authors.lastname: Moynihan
authors.forename: E N
authors.initials: EN
authors.lastname: Al-Mousa
authors.forename: M
authors.initials: M
authors.lastname: Campsey
authors.forename: R
authors.initials: R
authors.lastname: Gandhi
authors.forename: S
authors.initials: S
authors.lastname: Murphy
authors.forename: S
authors.initials: S
authors.lastname: Mattson
authors.forename: K A
authors.initials: KA
authors.lastname: Ryan
authors.forename: R
authors.initials: R
authors.lastname: Mesley
authors.forename: J
authors.initials: J
authors.lastname: Swanson
authors.forename: M N
authors.initials: MN
authors.lastname: Arshad
authors.forename: S J
authors.initials: SJ
authors.lastname: Marble
mesh_terms: D000077284:Abciximab; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology; D002309:Cardiology / Q000379:methods*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D004311:Double-Blind Method; D004617:Embolism / Q000517:prevention & control; D000077542:Eptifibatide; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D011446:Prospective Studies; D012306:Risk; D015607:Stents; D013329:Structure-Activity Relationship; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D001241:Aspirin; D000077284:Abciximab